Trial
NCT03782831
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital
Condition
Hepatocellular Carcinoma
Intervention
TACE
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-02